Mineralized hydrogel for bone defect treatment as well as preparation method and application of mineralized hydrogel

Through bionic mineralized hydrogels of bacterial cellulose, recombinant humanized collagen and hydroxyapatite, the problems of limited autologous bone sources and immune response in bone defect treatment are solved, and effective regeneration of bone tissue is achieved and Osteogenesis induction.

CN119015498APending Publication Date: 2024-11-26NANJING SIYUAN MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411174223.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Among the existing bone defect treatment methods, autologous bone sources are limited and immune responses are prone to occur, and the bionic bone stents have shortcomings in biocompatibility and osteogenesis induction.

Method used

Bionic mineralized hydrogels using bacterial cellulose, recombinant type I humanized collagen and hydroxyapatite were prepared by anti-solvent induction and sequential impregnation methods to form a composite hydrogel with a three-dimensional network structure for bone Treatment of defects.

Benefits of technology

This hydrogel can promote cell migration, osteogenic differentiation and bone tissue regeneration, significantly improve the therapeutic effect of bone defects, and solve the problems of biocompatibility and immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015498A_ABST
    Figure CN119015498A_ABST
Patent Text Reader

Abstract

The invention discloses mineralized hydrogel for bone defect treatment as well as a preparation method and application of the mineralized hydrogel, and belongs to the technical field of medicines. The mineralized hydrogel is prepared from bacterial cellulose, recombinant I type humanized collagen, ultrapure water, a CaCl2 solution and a Na2HPO4 solution. According to the invention, the composite hydrogel of the bacterial cellulose (BC) and the recombinant I-type humanized collagen (RHC) is prepared by a molecular anti-solvent induced co-assembly technology, so that efficient combination of the BC and the RHC is realized; and synthesizing hydroxyapatite by using a sequential dipping mineralization method so as to prepare the bacterial cellulose-recombinant I type humanized collagen biomimetic mineralized hydrogel (BC-RHC-M). The BC-RHC-M biomimetic mineralized hydrogel prepared in the invention has good mechanical properties, and can provide a certain support effect for bones. The BC-RHC-M biomimetic mineralized hydrogel prepared by the invention has excellent biocompatibility, has the effects of promoting cell migration, inducing osteogenic differentiation and the like, and can effectively promote bone tissue regeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to a mineralized hydrogel for treating bone defects and a preparation method and application thereof. Background Art

[0002] In recent years, the incidence of bone injuries has continued to rise, leading to an increasing demand for bone repair. The bone repair process mainly has three cross-stages: inflammation, bone formation, and bone remodeling. Bone transplantation is currently a recognized method for treating bone defects, but the source of autologous bone is limited and prone to immune response. With the development of bionics, bionic bone scaffolds that mimic the structure, mechanics, and biological properties of natural tissues have attracted widespread attention. Hydrogel is a promising material that has a porous three-dimensional network structure similar to the extracellular matrix, which facilitates the exchange of nutrients and has certain mechanical properties, playing a role in filling and supporting the defect.

[0003] The composition of natural bone is mainly composed of type I collagen fibers (organic part) and hydroxyapatite (inorganic part) embedded in the interfiber gaps. Hydroxyapatite is located in the gaps between collagen fibers, and its content in bone tissue is about 69%. It participates in metabolism in the body and has osteoconduction and osteoinduction properties. Bacterial cellulose, as a natural polysaccharide, has good biocompatibility, certain mechanical strength and degradability, and has received extensive attention in bone tissue engineering. Type I collagen can induce stem cells to differentiate into osteoblasts, achieving regeneration and repair of bone tissue, but most of them are of animal origin and have high immunogenicity. The recombinant type I humanized collagen has 100% homology with the amino acid sequence of human type I collagen, which solves the problem of immunogenicity of animal-derived collagen.

[0004] Inorganic components are combined with organic scaffolds, and a biomimetic mineralization method is used. Mineral ions enter the collagen gap under induction and deposit on the fiber surface to achieve intra-fiber mineralization. The present invention designs an anti-solvent induced and sequentially impregnated biomimetic mineralization method to achieve the combination of bacterial cellulose, recombinant type I humanized collagen and hydroxyapatite, thereby preparing a mineralized hydrogel with an osteogenic effect for the treatment of bone defects. Summary of the invention

[0005] The present invention provides a mineralized hydrogel for treating bone defects and a preparation method and application thereof, the mineralized hydrogel is a bacterial cellulose-recombinant type I humanized collagen biomimetic mineralized hydrogel which can promote growth, promote cell migration and induce osteogenic differentiation.

[0006] A mineralized hydrogel for treating bone defects.

[0007] The mineralized hydrogel is prepared from the following materials:

[0008] Bacterial cellulose, recombinant humanized type I collagen, CaCl2 solution, Na2HPO4 solution;

[0009] The mass ratio of the bacterial cellulose to the recombinant type I humanized collagen is 1:3 to 3:1.

[0010] Preferably, the mass ratio of the bacterial cellulose to the recombinant type I humanized collagen is 1:2 to 2:1.

[0011] Preferably, the concentration of the CaCl2 solution is 44.4 mg / mL.

[0012] Preferably, the concentration of the Na2HPO4 solution is 85.9 mg / mL.

[0013] A method for preparing the mineralized hydrogel for treating bone defects comprises the following steps:

[0014] S1: Preparation of bacterial cellulose solution:

[0015] The bacterial cellulose and 1-allyl-3-methylimidazole chloride are placed in a vacuum drying oven at 105° C. and dried for 3 hours; the dried bacterial cellulose is added to the 1-allyl-3-methylimidazole chloride, and heated and stirred in an oil bath until the bacterial cellulose is dissolved, thereby obtaining the bacterial cellulose solution;

[0016] S2: Preparation of bacterial cellulose-recombinant type I humanized collagen hydrogel:

[0017] After the bacterial cellulose solution is cooled, the recombinant type I humanized collagen is added, and heated and stirred in a water bath until dissolved; the mixed solution is taken out and placed in a mold, and after standing for 1 hour, it is immersed in anhydrous ethanol for solidification, and the anhydrous ethanol is replaced until the 1-allyl-3-methylimidazole chloride is removed; and then immersed in the ultrapure water, and the water is changed to obtain the bacterial cellulose-recombinant type I humanized collagen hydrogel;

[0018] S3: Preparation of bacterial cellulose-recombinant humanized type I collagen biomimetic mineralized hydrogel:

[0019] The CaCl2 solution and the Na2HPO4 solution are adjusted to pH and fixed temperature; at a fixed temperature, the bacterial cellulose-recombinant type I humanized collagen hydrogel is first immersed in the CaCl2 solution for 12 hours, taken out, rinsed with the ultrapure water, and then immersed in the Na2HPO4 solution for 12 hours. This process is a mineralization cycle; the bacterial cellulose-recombinant type I humanized collagen hydrogel is subjected to several mineralization cycles to obtain the bacterial cellulose-recombinant type I humanized collagen biomimetic mineralized hydrogel.

[0020] Preferably, in step S1, the bacterial cellulose is added to the 1-allyl-3-methylimidazole chloride to dissolve, and the oil bath temperature used is 100°C.

[0021] Preferably, in step S2, after the bacterial cellulose solution is cooled, the recombinant humanized type I collagen is added, and the water bath dissolution temperature used is 50°C.

[0022] Preferably, in step S2, the anhydrous ethanol is replaced three times until the 1-allyl-3-methylimidazole chloride is removed; and then the mixture is immersed in the ultrapure water, and the water is changed three times.

[0023] Preferably, in step S3, the pH of the CaCl2 solution and the Na2HPO4 solution are adjusted to 7.4; the fixed temperature of the CaCl2 solution and the Na2HPO4 solution is 37°C; and the number of mineralization cycles is 4 to 10 mineralization cycles.

[0024] Preferably, the application of the mineralized hydrogel for treating bone defects is in the preparation of a scaffold for treating bone defects.

[0025] The beneficial effects of the present invention are:

[0026] 1. The present invention utilizes that the 1-allyl-3-methylimidazole chloride solution of bacterial cellulose encounters the anti-solvent ethanol, which will induce the bacterial cellulose molecules in the solution to form strong intermolecular hydrogen bonds and assemble into a hydrogel with a three-dimensional network structure. Through this anti-solvent method, bacterial cellulose and recombinant type I humanized collagen are co-assembled to prepare a bacterial cellulose-recombinant type I humanized collagen composite hydrogel. This method can stably load the bioactive substance recombinant type I humanized collagen onto the bacterial cellulose, and has broad application prospects in the field of composite material preparation.

[0027] 2. Hydroxyapatite was synthesized by sequential impregnation method to prepare mineralized hydrogel that could induce osteogenic differentiation.

[0028] 3. In vitro studies have shown that mineralized hydrogels can promote cell migration, angiogenesis and osteogenic differentiation; in vivo studies have shown that composite hydrogels can promote bone tissue regeneration and have obvious therapeutic effects on bone defects. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 It is a schematic flow chart of the method for preparing BC-RHC-M mineralized hydrogel of the present invention.

[0030] Figure 2 It is a schematic structural flow chart of the method for preparing BC-RHC-M mineralized hydrogel of the present invention.

[0031] Figure 3 This is the appearance of the BC-RHC-M mineralized hydrogel in Example 1.

[0032] Figure 4 This is a scanning electron micrograph of the BC-RHC-M mineralized hydrogel in Example 1.

[0033] Figure 5 This is the compression performance curve of the BC-RHC-M mineralized hydrogel in Example 1.

[0034] Figure 6 The results of the experiment on the proliferation of bone marrow mesenchymal stem cells by BC-RHC-M mineralized hydrogel in Example 1 are shown.

[0035] Figure 7 The photograph (a) and migration rate statistics (b) of the BC-RHC-M mineralized hydrogel on bone marrow mesenchymal stem cells in Example 1 are shown.

[0036] Figure 8 The ALP staining photograph (a) and ALP quantification result (b) of the BC-RHC-M mineralized hydrogel in Example 1.

[0037] Fig. 9 This is an Alizarin red staining photograph of the BC-RHC-M mineralized hydrogel in Example 1.

[0038] Fig.10 This is a photograph of the BC-RHC-M mineralized hydrogel used to treat rat bone defects in Example 1.

[0039] Fig.11 These are micro-CT scan reconstruction images of the rat bone defects treated with BC-RHC-M mineralized hydrogel in Example 1 at the fourth and eighth weeks.

[0040] Fig.12 These are H&E staining images of bone tissue in rats with bone defects treated with BC-RHC-M mineralized hydrogel in Example 1 at the fourth and eighth weeks. DETAILED DESCRIPTION

[0041] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.

[0042] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0043] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0044] Bacterial cellulose is abbreviated as BC; recombinant humanized type I collagen is abbreviated as RHC; bacterial cellulose-recombinant humanized type I collagen hydrogel is abbreviated as BC-RHC; bacterial cellulose-recombinant humanized type I collagen biomimetic mineralized hydrogel is abbreviated as BC-RHC-M.

[0045] like Figure 1 and Figure 2 As shown, the preparation method of the mineralized hydrogel of the present invention comprises the following steps:

[0046] S1: dissolve BC to make BC solution;

[0047] S2: Add RHC to the BC solution until it dissolves, add ethanol to solidify, replace anhydrous ethanol to remove 1-allyl-3-methylimidazole chloride, and then soak in ultrapure water and replace the water to obtain BC-RHC;

[0048] S3: immersing the BC-RHC in a calcium chloride solution and disodium hydrogen phosphate solution in turn, and performing the cycle to obtain the BC-RHC-M.

[0049] In the present invention, BC-RHC-M can also be sterilized to obtain sterile BC-RHC-M. The sterilization method is moist heat sterilization, the sterilization temperature is 121° C., and the sterilization time is 15 minutes.

[0050] According to the solution of the embodiment of the present invention, BC-RHC-M has good biosafety and biocompatibility, can promote the osteogenic differentiation of bone marrow mesenchymal stem cells, and can effectively promote the repair of bone defects and the regeneration of bone tissue in vivo.

[0051] The following is a detailed description with specific embodiments:

[0052] Example 1

[0053] A BC-RHC-M dressing, the preparation method of which comprises the following steps:

[0054] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum oven and dry them at 105° C. for 3 h. Then add 0.1 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100° C. until BC is dissolved.

[0055] Step S2: After the BC solution is slightly cooled, 0.1 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold, let it stand for 1 hour, and then soak it in anhydrous ethanol to solidify. The anhydrous ethanol is changed 3 times until 1-allyl-3-methylimidazole chloride is removed, and then soaked in ultrapure water, changing the water 3 times to obtain BC-RHC.

[0056] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 4 mineralization cycles to obtain BC-RHC-M.

[0057] Example 2

[0058] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum oven and dry them at 105° C. for 3 h. Then add 0.1 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100° C. until BC is dissolved.

[0059] Step S2: After the BC solution is slightly cooled, 0.1 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold, let it stand for 1 hour, and then soak it in anhydrous ethanol to solidify. The anhydrous ethanol is changed 3 times until 1-allyl-3-methylimidazole chloride is removed, and then soaked in ultrapure water, changing the water 3 times to obtain BC-RHC.

[0060] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 10 mineralization cycles to obtain BC-RHC-M.

[0061] Example 3

[0062] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum oven and dry them at 105° C. for 3 h. Then add 0.1 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100° C. until BC is dissolved.

[0063] Step S2: After the BC solution is slightly cooled, 0.2 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold. After standing for 1 hour, soak it in anhydrous ethanol to solidify. Change the anhydrous ethanol three times until the 1-allyl-3-methylimidazole chloride is removed, and then soak it in ultrapure water, changing the water three times to obtain BC-RHC.

[0064] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 4 mineralization cycles to obtain BC-RHC-M.

[0065] Example 4

[0066] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum oven and dry them at 105° C. for 3 h. Then add 0.1 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100° C. until BC is dissolved.

[0067] Step S2: After the BC solution is slightly cooled, 0.2 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold. After standing for 1 hour, soak it in anhydrous ethanol to solidify. Change the anhydrous ethanol three times until the 1-allyl-3-methylimidazole chloride is removed, and then soak it in ultrapure water, changing the water three times to obtain BC-RHC.

[0068] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 10 mineralization cycles to obtain BC-RHC-M.

[0069] Example 5

[0070] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum drying oven and vacuum dry at 105°C for 3 hours. Then add 0.2 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100°C until BC is dissolved.

[0071] Step S2: After the BC solution is slightly cooled, 0.1 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold, let it stand for 1 hour, and then soak it in anhydrous ethanol to solidify. The anhydrous ethanol is changed 3 times until 1-allyl-3-methylimidazole chloride is removed, and then soaked in ultrapure water, changing the water 3 times to obtain BC-RHC.

[0072] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 4 mineralization cycles to obtain BC-RHC-M.

[0073] Example 6

[0074] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum drying oven and vacuum dry at 105°C for 3 hours. Then add 0.2 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100°C until BC is dissolved.

[0075] Step S2: After the BC solution is slightly cooled, 0.1 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold, let it stand for 1 hour, and then soak it in anhydrous ethanol to solidify. The anhydrous ethanol is changed 3 times until 1-allyl-3-methylimidazole chloride is removed, and then soaked in ultrapure water, changing the water 3 times to obtain BC-RHC.

[0076] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 10 mineralization cycles to obtain BC-RHC-M.

[0077] Example 7

[0078] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum drying oven and vacuum dry at 105°C for 3 hours. Then add 0.2 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100°C until BC is dissolved.

[0079] Step S2: After the BC solution is slightly cooled, 0.2 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold. After standing for 1 hour, soak it in anhydrous ethanol to solidify. Change the anhydrous ethanol three times until the 1-allyl-3-methylimidazole chloride is removed, and then soak it in ultrapure water, changing the water three times to obtain BC-RHC.

[0080] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 4 mineralization cycles to obtain BC-RHC-M.

[0081] Example 8

[0082] Step S1: Place BC and 1-allyl-3-methylimidazole chloride in a vacuum drying oven and vacuum dry at 105°C for 3 hours. Then add 0.2 g of dried BC to 5 g of 1-allyl-3-methylimidazole chloride, and heat and stir in an oil bath at 100°C until BC is dissolved.

[0083] Step S2: After the BC solution is slightly cooled, 0.2 g of RHC is added, and heated and stirred in a 50°C water bath until dissolved. Take it out and put it into a mold. After standing for 1 hour, soak it in anhydrous ethanol to solidify. Change the anhydrous ethanol three times until the 1-allyl-3-methylimidazole chloride is removed, and then soak it in ultrapure water, changing the water three times to obtain BC-RHC.

[0084] Step S3: Prepare 44.4 mg / mL CaCl2 solution and 85.9 mg / mL Na2HPO4 solution, and adjust the pH to 7.4. At 37°C, BC-RHC was immersed in CaCl2 solution for 12 hours, taken out and rinsed with ultrapure water, and then immersed in Na2HPO4 solution for 12 hours. This process was regarded as one mineralization cycle. The hydrogel was subjected to 10 mineralization cycles to obtain BC-RHC-M.

[0085] Figure 3 The figure shows the appearance of BC-RHC-M prepared in Example 1 of the present invention. Figure 3 In the figure, a is BC-RHC, and b is BC-RHC-M. It can be seen from the figure that after biomimetic mineralization, the surface of the hydrogel becomes obviously white, which is caused by the deposition of hydroxyapatite.

[0086] Figure 4 The scanning electron microscope image of BC-RHC-M prepared according to Example 1 of the present invention is shown. It can be seen that the composite hydrogel is a porous structure with obvious particle deposition on the surface.

[0087] Figure 5 The stress-strain curve of the compression of BC-RHC-M prepared according to Example 1 of the present invention is shown. Figure 5 It can be seen that compared with BC hydrogel, BC-RHC-M has higher compressive mechanical properties, that is, greater strength, and plays a supporting role in the bone defect site.

[0088] Figure 6 The figure shows the cell proliferation at different times after co-culture of bone marrow mesenchymal stem cells (BMSC) and BC-RHC-M prepared according to Example 1 of the present invention. BMSC cells with good morphology were cultured at 2×10 4 The density of cells / well was inoculated into the lower chamber of the 24-well transwell plate and placed in a cell culture incubator for 24 hours. The BC-RHC-M hydrogel was placed in the upper chamber, and the control group (no BC-RHC-M was added, but other conditions were the same) did not place the material. After 1d, 3d, and 5d of culture, the chamber was removed, the original culture medium was discarded, and α-MEM culture medium containing 10% CCK-8 was added to each well after washing with PBS and avoiding light. After incubation in the incubator for 1h, it was transferred to a 96-well plate and the absorbance value of the well plate at a wavelength of 450nm was detected using an ELISA reader. As can be seen from the figure, with the increase of culture time, the survival rate of cells in each group increased; compared with the control group, the cell survival rate of the BC-RHC-M group was higher, indicating that mineralized hydrogel can significantly promote cell proliferation.

[0089] Figure 7 The crystal violet staining photograph (a) and the quantitative statistical graph (b) of cell migration of BMSCs by BC-RHC-M prepared according to Example 1 of the present invention are shown. BMSCs with good morphology were digested with trypsin and heated at 2.5×10 4 The density of cells / mL was diluted into a cell suspension using serum-free culture medium, 200 μL of cell suspension was added to the transwell chamber on the upper layer of the 24-well plate, and 500 μL of serum-containing culture medium was added to the lower layer. After culturing in an incubator for 24 hours, crystal violet staining was used, and photos were taken and the migration rate was analyzed. The results are shown in the figure. Compared with the control group (no BC-RHC-M was added, but other conditions were the same), the number of migrated cells in the BC-RHC-M group increased significantly, proving that the BC-RHC-M composite hydrogel can significantly promote cell migration.

[0090] Figure 8The alkaline phosphatase staining photo (a) and alkaline phosphatase quantitative results (b) of BC-RHC-M prepared according to Example 1 of the present invention and co-cultured with BMSC cells after 14 days of osteogenic induction are shown. BMSC cells with good growth status were inoculated in the lower chamber of a 6-well transwell plate. After incubation for 24 hours, BC-RHC-M was placed in the upper chamber for continued culture, and the control group (no BC-RHC-M was added, but other conditions were the same) was only placed in the chamber. When it is in the logarithmic growth phase, the osteogenic induction solution is replaced. After 7 days of osteogenic induction, the original osteogenic induction solution in the well was discarded, washed with PBS, and paraformaldehyde was added to fix the cells at room temperature for 30 minutes, and washed three times with PBS. 500 μL BCPI / NBT staining working solution was added to each well, incubated at room temperature for 30 minutes, washed twice with PBS, and observed and photographed using a microscope. After 7 days of osteogenic induction, the 6-well plate was placed on ice, the osteogenic induction solution in the well was discarded, and washed three times with PBS. Add cell lysis buffer on ice to lyse the cells for 20 minutes, and pipette the cells every 5 minutes. Centrifuge under low temperature conditions and aspirate the supernatant. Measure the absorbance of the standard solution and sample at 405nm, and establish a standard curve to calculate the ALP activity. As shown in the figure, the control group is stained with a lighter blue-purple color, indicating that the cells have been osteogenic. The blue-purple color of the BC-RHC-M group is significantly deepened, indicating that the expression of alkaline phosphatase in the cells of the BC-RHC-M group is significantly higher than that of the control group, proving that BC-RHC-M can induce osteogenic differentiation of bone marrow mesenchymal stem cells.

[0091] Fig. 9 The alizarin red staining photo after 21 days of osteogenic induction under the conditions of co-culture of BC-RHC-M mineralized hydrogel and BMSC cells prepared according to Example 1 of the present invention is shown. The BC-RHC-M hydrogel was placed in the upper chamber, and the control group (no BC-RHC-M was added, but other conditions were the same) did not place the material, and osteogenic induction was carried out for 21 days, the original osteogenic induction solution was discarded, and PBS was used to wash three times. 4% paraformaldehyde was added to each well to fix the cells for 30min and washed three times with PBS. 2mL of alizarin red solution was added to each well, stained at 37°C in dark for 1h, washed three times with PBS, observed under a microscope and photographed. Alizarin red staining can dye the deposited calcium nodules dark red. The larger the red area, the darker the color, the more calcium nodules are formed, and the stronger the osteogenic differentiation ability. As shown in the figure, compared with the control group, the BC-RHC-M group has the deepest red and the largest area, indicating that the most calcium nodules are generated, which can prove that BC-RHC-M mineralized hydrogel can induce BMSC to undergo osteogenic differentiation.

[0092] Six-week-old male Sprague-Dawley rats were selected. After one week of adaptive feeding, they were weighed and anesthetized with sodium pentobarbital. After the left leg of the rat was shaved and disinfected with iodine, the skin at the femur of the rat was cut to expose the femur. A low-speed dental drill was used to produce a cylindrical defect (depth: 3mm, diameter: 3mm) perpendicular to the femur of the rat. During this period, cold saline was dripped with a syringe continuously to prevent necrosis caused by friction overheating of the drill bit. After pressing with sterile gauze to stop bleeding, the hydrogel material was immediately implanted to fill the defect, and the material was fitted to the defect as much as possible. The incised muscles and skin were sutured with sterile surgical sutures respectively. The control group did not implant the material. Immediately after the operation, the right leg of the rat was injected intramuscularly with penicillin once a day for three consecutive days to prevent wound infection. The various vital signs of the rat were closely observed until they were stable and then placed in a cage.

[0093] Four and eight weeks after implantation, the rats were euthanized, and the femurs were collected and fixed in 4% paraformaldehyde at room temperature for 24 h, and then stored at 4°C for subsequent experiments. Fig.10 The tissue photographs of rat femoral defects treated with BC-RHC-M mineralized hydrogel prepared according to Example 1 of the present invention at weeks 4 and 8 are shown. Compared with the control group (no BC-RHC-M was added, but other conditions were the same), the defect site in the BC-RHC-M group had almost completely regenerated new bone tissue, and the surface was relatively intact, indicating that BC-RHC-M can promote the repair of bone defects and accelerate bone regeneration.

[0094] Micro-CT analysis was performed on bone tissues at 4 and 8 weeks. Fig.11 The three-dimensional micro-CT image and representative cross-sectional micro-CT image of the femoral defect of rats treated with BC-RHC-M mineralized hydrogel prepared according to Example 1 of the present invention are shown. As can be seen from the figure, at week 8, there are different degrees of repair compared with week 4. The control group (no BC-RHC-M is added, but other conditions are the same) repairs slowly, and defects can still be seen, while the BC-RHC-M group can see complete bone tissue, uniform thickness distribution, and complete cortical bone morphology, indicating that BC-RHC-M has a significant therapeutic effect on bone defects and can accelerate bone regeneration.

[0095] Fig.12H&E staining of bone tissue of diabetic bone defects in rats treated with BC-RHC-M mineralized scaffolds prepared according to Example 1 of the present invention at 4 weeks and 8 weeks is shown. Compared with the control group (no BC-RHC-M was added, but other conditions were the same), the BC-RHC-M group showed a certain tissue regeneration effect, the defect area was significantly reduced, and the defect was almost filled with new bone tissue, indicating its excellent bone regeneration ability. It can be proved that BC-RHC-M has a significant therapeutic effect on bone defects and can promote bone tissue regeneration.

Claims

1. A mineralized hydrogel for treating bone defects, characterized in that: The mineralized hydrogel is prepared from the following materials: Bacterial cellulose, recombinant humanized type I collagen, CaCl2 solution, Na2HPO4 solution; The mass ratio of the bacterial cellulose to the recombinant type I humanized collagen is 1:3 to 3:

1.

2. The mineralized hydrogel for treating bone defects according to claim 1, characterized in that: The mass ratio of the bacterial cellulose to the recombinant type I humanized collagen is 1:2 to 2:

1.

3. The mineralized hydrogel for treating bone defects according to claim 1, characterized in that: The concentration of the CaCl2 solution is 44.4 mg / mL.

4. The mineralized hydrogel for treating bone defects according to claim 1, characterized in that: The concentration of the Na2HPO4 solution is 85.9 mg / mL.

5. A method for preparing the mineralized hydrogel for treating bone defects according to any one of claims 1 to 4, characterized in that: The following steps are involved: S1: Preparation of bacterial cellulose solution: The bacterial cellulose and 1-allyl-3-methylimidazole chloride are placed in a vacuum drying oven at 105° C. and dried for 3 hours; the dried bacterial cellulose is added to the 1-allyl-3-methylimidazole chloride, and heated and stirred in an oil bath until the bacterial cellulose is dissolved, thereby obtaining the bacterial cellulose solution; S2: Preparation of bacterial cellulose-recombinant type I humanized collagen hydrogel: After the bacterial cellulose solution is cooled, the recombinant type I humanized collagen is added, and heated and stirred in a water bath until dissolved; the mixed solution is taken out and placed in a mold, and after standing for 1 hour, it is immersed in anhydrous ethanol for solidification, and the anhydrous ethanol is replaced until the 1-allyl-3-methylimidazole chloride is removed; and then immersed in the ultrapure water, and the water is changed to obtain the bacterial cellulose-recombinant type I humanized collagen hydrogel; S3: Preparation of bacterial cellulose-recombinant humanized type I collagen biomimetic mineralized hydrogel: The CaCl2 solution and the Na2HPO4 solution are adjusted to pH and fixed temperature; at a fixed temperature, the bacterial cellulose-recombinant type I humanized collagen hydrogel is first immersed in the CaCl2 solution for 12 hours, taken out, rinsed with the ultrapure water, and then immersed in the Na2HPO4 solution for 12 hours. This process is a mineralization cycle; the bacterial cellulose-recombinant type I humanized collagen hydrogel is subjected to several mineralization cycles to obtain the bacterial cellulose-recombinant type I humanized collagen biomimetic mineralized hydrogel.

6. The method for preparing a mineralized hydrogel for treating bone defects according to claim 5, characterized in that: In step S1, the bacterial cellulose is added into the 1-allyl-3-methylimidazole chloride to dissolve, and the oil bath temperature used is 100°C.

7. The method for preparing a mineralized hydrogel for treating bone defects according to claim 5, characterized in that: In step S2, after the bacterial cellulose solution is cooled, the recombinant humanized type I collagen is added, and the water bath dissolution temperature used is 50°C.

8. The method for preparing a mineralized hydrogel for treating bone defects according to claim 5, characterized in that: In step S2, the absolute ethanol is replaced three times until the 1-allyl-3-methylimidazole chloride is removed; and then the mixture is immersed in the ultrapure water, and the water is changed three times.

9. The method for preparing a mineralized hydrogel for treating bone defects according to claim 5, characterized in that: In step S3, the pH of the CaCl2 solution and the Na2HPO4 solution are adjusted to 7.4; the fixed temperature of the CaCl2 solution and the Na2HPO4 solution is 37°C; and the number of mineralization cycles is 4 to 10 mineralization cycles.

10. The use of the mineralized hydrogel for treating bone defects according to claim 1 or the mineralized hydrogel for treating bone defects prepared in claim 5 is in the preparation of a scaffold for treating bone defects.